2 documents found, page 1 of 1
Plasma von Willebrand factor as a predictor of survival in pulmonary arterial h...
Lopes,A.A.; Barreto,A.C.; Maeda,N.Y.; Cícero,C.; Soares,R.P.S.; Bydlowski,S.P.; Rich,S.Biomarkers have been identified for pulmonary arterial hypertension, but are less well defined for specific etiologies such as congenital heart disease-associated pulmonary arterial hypertension (CHDPAH). We measured plasma levels of eight microvascular dysfunction markers in CHDPAH, and tested for associations with survival. A cohort of 46 inoperable CHDPAH patients (age 15.0 to 60.2 years, median 33.5 years, ...
Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertensio...
Barreto,A.C.; Maeda,N.Y.; Soares,R.P.S.; Cícero,C.; Lopes,A.A.We investigated whether chronic rosuvastatin administration could improve the abnormalities of the circulating levels of vascular dysfunction markers in pulmonary arterial hypertension (PAH). Sixty patients, aged 13 to 60 years, with idiopathic (N = 14) or congenital heart disease-associated PAH (N = 46) were equally but randomly assigned to rosuvastatin treatment (10 mg a day, orally) or placebo for 6 months i...